A Phase 2, Randomized, Blinded, 5-period Cross-over, Placebo and Active Controlled, Multicenter, Dose-finding Study Comparing Single Doses of Formoterol 2.25 microg, 4.5 microg, and 9 microg Delivered Via Symbicort pMDI and Foradil 12 microg Evaluating the Relative Bronchodilating Effects and Safety in Children.

Trial Profile

A Phase 2, Randomized, Blinded, 5-period Cross-over, Placebo and Active Controlled, Multicenter, Dose-finding Study Comparing Single Doses of Formoterol 2.25 microg, 4.5 microg, and 9 microg Delivered Via Symbicort pMDI and Foradil 12 microg Evaluating the Relative Bronchodilating Effects and Safety in Children.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2013

At a glance

  • Drugs Formoterol (Primary) ; Budesonide; Budesonide/formoterol
  • Indications Asthma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms CHASE2
  • Most Recent Events

    • 28 Mar 2012 Planned number of patients changed from 52 to 86 as reported by European Clinical Trials Database record.
    • 07 Feb 2012 Actual patient number (54) added as reported by ClinicalTrials.gov.
    • 07 Feb 2012 Actual end date ( Dec 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top